Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29040649 | 0.94 | MAPT (0.57) | MAPTGAAMAP1LC3BPOLBLMNA | |
| SCHEMBL428432 | 0.91 | MAP1LC3B (0.55) | MAPTGAAMAP1LC3BPOLBLMNA | |
| SCHEMBL10672428 | 0.89 | MAPT (0.77) | MAPTGAAMAP1LC3BPOLBTDP1 | |
| SCHEMBL25374648 | 0.85 | GAA (0.47) | MAPTGAAMAP1LC3BPOLBLMNA | |
| SCHEMBL25372756 | 0.82 | GAA (0.45) | MAPTGAAMAP1LC3BPOLBLMNA | |
| SCHEMBL735604 | 0.79 | ESR2 (0.50) | MAPTGAAMAP1LC3BPOLBLMNA | |
| SCHEMBL7004274 | 0.79 | ESR2 (0.50) | MAPTGAAMAP1LC3BPOLBLMNA | |
| SCHEMBL7004062 | 0.79 | ESR2 (0.50) | MAPTGAAMAP1LC3BPOLBLMNA | |
| SCHEMBL11821558 | 0.78 | MAPT (0.63) | MAPTGAAMAP1LC3BPOLBTDP1 | |
| SCHEMBL14941706 | 0.78 | MAPT (0.63) | MAPTGAAPOLBTDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509579-B2 | Thermoplastic resin and optical lens including same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2025-12-30 | — | — | US | disclosed |
| CN-115996931-B | Cyclic diol compound, process for producing the compound, and use of the compound | 新日本理化株式会社 | 2025-04-01 | — | — | CN | disclosed |
| US-20230399510-A1 | THERMOPLASTIC RESIN AND OPTICAL LENS INCLUDING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| EP-4239010-A1 | THERMOPLASTIC RESIN AND OPTICAL LENS INCLUDING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-09-06 | — | — | EP | disclosed |
| CN-116323753-A | Thermoplastic resin and optical lens comprising the same | 三菱瓦斯化学株式会社 | 2023-06-23 | — | — | CN | disclosed |
| CN-115996931-A | Cyclic diol compound, process for producing the compound, and use of the compound | 新日本理化株式会社 | 2023-04-21 | — | — | CN | disclosed |
| WO-2022091990-A1 | CYCLIC DIOL COMPOUND, PRODUCTION METHOD FOR SAID COMPOUND, AND USE OF SAID COMPOUND | 新日本理化株式会社 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022091996-A1 | THERMOPLASTIC RESIN AND OPTICAL LENS INCLUDING SAME | 三菱瓦斯化学株式会社 | 2022-05-05 | — | — | WO | disclosed |
| US-9593069-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160039740-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2016-02-11 | — | — | US | disclosed |
| EP-2144889-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC S.r.l. (IT) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007051062-A2 | SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-6350749-B1 | SODIUM CHANNEL MODULATORS, ANTIARRHYTHMIA AND HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS, ANGINA PECTORIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-26 | — | — | US | disclosed |
| EP-0414952-A1 | Dithiolane derivatives | NIHON NOHYAKU CO., LTD. (JP) | 1991-03-06 | — | — | EP | disclosed |
| US-3947449-A | Tetrahydroacridones having chemotherapeutic action and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039740-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | MAPT 259/4885GAA 48/4885MAP1LC3B 602/4885 |
| US-12509579-B2 | Thermoplastic resin and optical lens including same | RIF1, POT1, LAS1L | MAPT 932/4885GAA 921/4885MAP1LC3B 35/4885 |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | C3AR1, C5AR1, C5AR2 | MAPT 4656/4885GAA 3421/4885MAP1LC3B 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.